Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.
about
Screening of functional and positional candidate genes in families with common variable immunodeficiencyThe transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophilsT-cell abnormalities in common variable immunodeficiency: the hidden defectUpdate in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditionsAutoimmune manifestations in common variable immunodeficiency.The ITP syndrome: pathogenic and clinical diversity.Granulomatous disease in common variable immunodeficiency.Autoimmunity in primary immune deficiency: taking lessons from our patients.Autoimmune cytopenias in common variable immunodeficiency.A decreased frequency of regulatory T cells in patients with common variable immunodeficiencyAnalysis of TACI mutations in CVID & RESPI patients who have inherited HLA B*44 or HLA*B8.Common variable immunodeficiency: etiological and treatment issues.The many faces of common variable immunodeficiency.How I treat common variable immune deficiency.Toll-like receptor 7 and 9 defects in common variable immunodeficiency.Autoimmunity in common variable immunodeficiency.Role of B cells in common variable immune deficiency.Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID)Morbidity and mortality in common variable immune deficiency over 4 decadesInnate control of B cell responses.The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiencyDifferential induction of plasma cells by isoforms of human TACI.IgH sequences in common variable immune deficiency reveal altered B cell development and selection.Perspectives on common variable immune deficiency.Toll-like receptor function in primary B cell defects.Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome.Toll-like receptor signaling in primary immune deficiencies.TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development.TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes.Genome-wide association identifies diverse causes of common variable immunodeficiencyRelevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromesCVID-associated TACI mutations affect autoreactive B cell selection and activation.Memory B cells in common variable immunodeficiency: clinical associations and sex differences.The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function.Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease.Genetics of hypogammaglobulinemia: what do we really know?New frontiers of primary antibody deficiencies.Treatment of systemic lupus erythematosus: new advances in targeted therapy.Common variable immunodeficiency (CVID): exploring the multiple dimensions of a heterogeneous disease.
P2860
Q21263125-50040670-3728-4F8C-A339-779B65744324Q24293739-36FB0559-D2B1-4012-9E74-E6FB3DA1A1F0Q24648880-99C0B8C5-548B-4782-8EC3-EEE40E7B3685Q26751451-02C9724C-C7A5-4C44-B98F-63A3287BFFEFQ28240370-4E2E0A9F-7171-45CE-BC40-A6056E5A4D54Q33378880-DB45945F-8D36-4F73-BF14-D5B31839561DQ33384235-DF9C095A-B728-42C8-B93B-28842134EE80Q33386034-B2B6723C-669F-4826-AD26-BD3E36BCDACDQ33394794-10A40B91-A216-4775-BE56-804B4D9DA7D5Q33402558-E56AA2FA-D937-42DD-A49D-30C97498FC95Q33489543-66E0AE02-11C4-4609-A34B-0F2C23E5C35FQ33506199-E8904B3E-B472-47B7-8D6A-11D6EB7756F2Q33621805-05530274-D7DE-4885-9122-5C9FA13FDDABQ33790739-43F62DF7-3909-4B4B-B91A-96CE587FDA0CQ33997226-0C99D96A-E098-46EB-9FD0-83FD5FFF4A44Q34013669-AE79FBF3-E8B1-4CCC-8EF5-B1B28B7E3647Q34056308-2739D103-1187-43D2-8845-058F04D8D33CQ34071102-5A2A1DDA-D4FE-4114-873A-33C603BAF393Q34115373-B3FC0553-1F92-4437-AFBF-1CD06E51CCABQ34241472-7CCEE75B-A64C-4A65-96FE-34C756A846EDQ34958353-348BFE58-1E52-4016-B07D-DB043D9253DFQ35065333-BC8CD764-FF9C-40D1-93ED-B8592680A836Q35171263-E2DD65D1-A525-42E5-A46A-A6A7F155C53AQ36096339-F9AEC4CD-85A2-4A85-931A-5495D9A4CE74Q36190407-69098F85-080B-4CF4-B3F1-C5DCA1A1BF2AQ36190430-3FF608AE-2A96-4BAA-84F2-C072F81BB91EQ36190444-245D3C76-1391-47E5-9A1E-7B3DFFB89717Q36238886-ACA36282-9046-439C-8ECF-B1934CE61104Q36269275-0B8C6468-1FFF-4A9D-A86E-F39F25DA04E4Q36823203-8F13FF35-0ECC-449F-B837-C0A0F4A0D699Q36823272-AFB5F677-BA15-42D0-990B-CCE0BF979FB0Q37116935-33F810AA-C3ED-4AF4-BC87-4F22BCF2B278Q37206886-71EE988F-663D-4523-9245-843536D8BB66Q37216274-5816999D-9195-43EF-8FCC-6B8062C38707Q37351039-E63CEE46-7CEA-4D44-8183-8148A640A7BEQ37478243-0D219C7B-8171-4663-8F28-BF3CFA2960E2Q37571008-6EE5223F-353C-4E47-9824-D6F8C470545BQ37951367-3A8854CE-E8B9-49F6-9EF1-FF13E78FBA06Q37974990-26C924FE-AD48-4CF0-B7C0-4F4FD83CDA1AQ37980927-CAABE171-6C66-41BC-A718-1E7B820D896A
P2860
Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@ast
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@en
type
label
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@ast
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@en
prefLabel
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@ast
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@en
P2093
P2860
P50
P1476
Transmembrane activator and ca ...... gic outcomes in heterozygotes.
@en
P2093
Bodo Grimbacher
Lin Radigan
Timothy W Behrens
Ulrich Salzer
P2860
P304
P356
10.1016/J.JACI.2007.10.001
P407
P577
2007-11-01T00:00:00Z